DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 207 filers reported holding DENALI THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $377 | -27.4% | 18,255 | +3.9% | 0.00% | -25.0% |
| Q2 2023 | $519 | +46.6% | 17,576 | +14.3% | 0.00% | +33.3% |
| Q1 2023 | $354 | -29.1% | 15,380 | -14.4% | 0.00% | -25.0% |
| Q4 2022 | $499 | -99.9% | 17,959 | +12.7% | 0.00% | -20.0% |
| Q3 2022 | $489,000 | +6.8% | 15,942 | +2.4% | 0.01% | +25.0% |
| Q2 2022 | $458,000 | -4.4% | 15,562 | +4.5% | 0.00% | 0.0% |
| Q1 2022 | $479,000 | -66.5% | 14,893 | -53.5% | 0.00% | -20.0% |
| Q4 2021 | $1,428,000 | +75.0% | 32,024 | +97.9% | 0.01% | -28.6% |
| Q3 2021 | $816,000 | -39.5% | 16,184 | -5.8% | 0.01% | -36.4% |
| Q2 2021 | $1,348,000 | +163.8% | 17,181 | +91.9% | 0.01% | -42.1% |
| Q1 2021 | $511,000 | -37.9% | 8,953 | -8.9% | 0.02% | -38.7% |
| Q4 2020 | $823,000 | +135.1% | 9,828 | +0.5% | 0.03% | +106.7% |
| Q3 2020 | $350,000 | +44.0% | 9,779 | -2.8% | 0.02% | +36.4% |
| Q2 2020 | $243,000 | – | 10,064 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,705,039 | $343,645,000 | 25.68% |
| Casdin Capital, LLC | 1,500,000 | $66,900,000 | 1.89% |
| Flagship Pioneering Inc. | 2,619,968 | $116,851,000 | 1.81% |
| SECTORAL ASSET MANAGEMENT INC | 189,600 | $8,456,000 | 1.27% |
| Integral Health Asset Management, LLC | 100,000 | $4,460,000 | 1.23% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $239,479,000 | 0.86% |
| Goldstream Capital Management Ltd | 78,418 | $3,497,000 | 0.86% |
| Yiheng Capital Management, L.P. | 335,184 | $14,949,000 | 0.76% |
| GILDER GAGNON HOWE & CO LLC | 2,900,114 | $129,345,000 | 0.74% |
| Artal Group S.A. | 600,000 | $26,760,000 | 0.73% |